iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
Yahoo Finance · Apr 8, 2026 · iBio, Inc. Common Stock (IBIO)
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or “the Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced IBIO-600 has received Clinical Trial Notification (CTN) acknowledgement from Australia’
Not investment advice. Cached headline, not a full reprint.